Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2026-05-12 Declaration of Voting R…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Kommuniké från årsstämma i Xspray Pharma AB (publ) 12 maj 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a press release summarizing the resolutions and voting outcomes from the Xspray Pharma AB annual general meeting held on 12 May 2026. It lists decisions on approval of accounts, discharge of liability, dividend, board and auditor elections, incentive programs, and share issuance authorizations—all outcomes of shareholder votes. This fits the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-12 Swedish
Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release titled “Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026” summarizing the resolutions passed at the AGM (adoption of financials, board elections, LTIP programs, share authorizations, etc.). It is not the full AGM slide deck or financial report itself but an official announcement of the voting outcomes and resolutions from the AGM. Hence it fits the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-12 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 100% confidence The document is a notification from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a shareholder's holdings in XSpray Pharma AB. It details the number of shares and voting rights held before and after a transaction, the percentage ownership, and the legal basis for the disclosure. The document is a flagging notification about share ownership crossing a threshold, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding information, with no financial statements or other report content. Therefore, it is classified as MRQ with high confidence.
2026-05-04 Swedish
Nytt antal aktier och röster i Xspray Pharma efter nyemission april 2026
Share Issue/Capital Change Classification · 100% confidence The document is a press release dated April 30, 2026, announcing a change in the number of shares and voting rights in Xspray Pharma following a new share issuance (nyemission). It details the increase in outstanding shares and share capital due to a rights issue and overallotment. The content focuses on capital structure changes and share issuance, with no financial statements or detailed financial performance data. The document length is short (2413 characters) and it is clearly an announcement of a capital change event rather than a full financial report or detailed investor presentation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2026-04-30 Swedish
New number of shares and votes in Xspray Pharma after new share issue April 2026
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the number of shares and votes due to a new share issue and over-allotment issue. It provides details on the increase in shares and share capital. There is no detailed financial report or analysis, only an announcement of a capital change event. The document length is short (2323 characters), and it is clearly an announcement rather than a full report. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2026-04-30 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Delårsrapport Januari - mars 2026' which translates to 'Interim Report January - March 2026'. It contains detailed financial data for Q1 2026, including net sales, profit before tax, earnings per share, cash flow, and balance sheet figures. It also includes management commentary (VD-ord), key events during and after the quarter, product and market information, and shareholder data. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with a quarterly or interim financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-28 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.